|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 403/12 | |
| A61K 31/497 | |||
| A61P 35/00 |
| (11) | Number of the document | 3386975 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16813274.4 |
| Date of filing the European patent application | 2016-12-01 | |
| (97) | Date of publication of the European application | 2018-10-17 |
| (45) | Date of publication and mention of the grant of the patent | 2019-09-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/064379 |
| Date | 2016-12-01 |
| (87) | Number | WO 2017/100071 |
| Date | 2017-06-15 |
| (30) | Number | Date | Country code |
| 201562263908 P | 2015-12-07 | US |
| (72) |
ENNETT-SHEPARD, Alessandra B., US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE |
| 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE |